Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $8.0 million.

  • Arcus Biosciences' Cash from Financing Activities fell 8333.33% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.0 million, marking a year-over-year decrease of 2907.8%. This contributed to the annual value of $277.0 million for FY2024, which is 73939.39% up from last year.
  • Latest data reveals that Arcus Biosciences reported Cash from Financing Activities of $8.0 million as of Q3 2025, which was down 8333.33% from $52.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Cash from Financing Activities peaked at $229.0 million during Q1 2024, and registered a low of -$2.0 million during Q4 2024.
  • Its 5-year average for Cash from Financing Activities is $41.2 million, with a median of $8.0 million in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 3631311.48% in 2021, then crashed by 16666.67% in 2024.
  • Arcus Biosciences' Cash from Financing Activities (Quarter) stood at $11.3 million in 2021, then fell by 2.92% to $11.0 million in 2022, then crashed by 72.73% to $3.0 million in 2023, then tumbled by 166.67% to -$2.0 million in 2024, then surged by 500.0% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q3 2025, $52.0 million for Q2 2025, and $142.0 million during Q1 2025.